Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party.

Archive ouverte

Penack, Olaf | Peczynski, Christophe | Koenecke, Christian | Polge, Emmanuelle | Sanderson, Robin | Yakoub-Agha, Ibrahim | Fegueux, Nathalie | Daskalakis, Michael | Collin, Matthew | Dreger, Peter | Kröger, Nicolaus | Schanz, Urs | Bloor, Adrian | Ganser, Arnold | Besley, Caroline | Wulf, Gerald G. | Novak, Urban | Moiseev, Ivan | Schoemans, Hélène | Basak, Grzegorz W. | Chabannon, Christian | Sureda Balari, Anna | Glass, Bertram | Peric, Zinaida

Edité par CCSD ; Frontiers -

International audience. We investigated ≥ grade 3 (CTC-AE) organ toxicities for commercial CD19 chimeric antigen receptor T cell (CAR-T cell) products in 492 patients (Axi-Cel; n = 315; Tisa-Cel; n = 177) with Large B-cell Lymphoma in the European Society for Blood and Marrow Transplantation (EBMT) CAR-T registry. The incidence of ≥ grade 3 organ toxicities during the first 100 days after CAR-T was low and the most frequent were: renal (3.0%), cardiac (2.3%), gastro-intestinal (2.3%) and hepatic (1.8%). The majority occurred within three weeks after CAR-T cell therapy. Overall survival was 83.1% [79.8-86.5; 95% CI] at 3 months and 53.5% [49-58.4; 95% CI] at one year after CAR-T. The most frequent cause of death was tumour progression (85.1%). Non-relapse mortality was 3.1% [2.3-4.1; 95% CI] at 3 months and 5.2% [4.1-6.5; 95% CI] at one year after CAR-T. The most frequent causes of non-relapse mortality were cell-therapy-related toxicities including organ toxicities (6.4% of total deaths) and infections (4.4% of total deaths). Our data demonstrates good safety in the European real-world setting.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion